In a third round of testing, the new drug Ruboxistaurin has proven its worth in patients with diabetic retinopathy.
The study compared the outcomes of two previous tests involving placebo-controlled research on a combined 813 patients.
Of those people participating in the studies, four hundred-twelve received the actual medication, while the remainder received only the placebo.
Approximately twenty-five of the patients receiving Ruboxistaurin saw controlled vision loss of the period of three years, nineteen actually gained fifteen letters or more on follow-up exams, while thirty lost fifteen or more letters.
This was compared to those who received the placebo, of which forty-one saw controlled vision loss, just nine saw notable improvement, and a whopping forty-six saw drastic vision decline.
There were no safety concerns noted in the report of findings. A little more than a quarter of the patients receiving the medication required laser treatment to cauterize abnormal blood vessels in the eye, but more than thirty-five percent of those receiving the placebo required the procedure.
The researchers believe that the benefits of Ruboxistaurin in patients with diabetic retinopathy are a result of its limiting macular edema (swelling or thickening of the macula).
You can read more about these findings in the full article.
Leave Your Response